secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018823
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q1 revenue $42.2M (+45% YoY), raises FY2023 guidance to $190M-$196M
--------------------------------------------------------------------------------

- Revenue $42.2M, up 45% YoY; net loss per share ($0.23) vs ($0.16) prior year.
- Gross margin 80.9% (down from 82.3%); adjusted EBITDA loss $10.0M vs $6.4M.
- Raises full-year 2023 revenue guidance to $190M-$196M (prior $187M-$193M).
- Direct sales channel accounted for 79% of sales (up from 63%).
- Clinical study data: 97.3% patient satisfaction at 36 months; low recurrence 0.9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023018823/0000950170-23-018823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017023018823/tmci-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer